| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
S-26131 (S26131) is a novel and selective MT1 and MT2 antagonist, with Ki values of 0.5 and 112 nM for MT1 and MT2, respectively.
| Targets |
MT1
Human Melatonin Receptor Subtype 1 (MT1) and Subtype 2 (MT2) [1] |
|---|---|
| ln Vitro |
S26131 has KB values of 5.32 and 143 nM, respectively, and functions as an antagonist of MT1 and MT2 couplers[1].
S-26131 (referred to as compound 5 in the literature, as a specific "S-26131" name is not explicitly assigned) demonstrated high binding affinity for the human MT1 receptor with a Ki value of 0.05 ± 0.01 nM. [1] S-26131 showed significantly lower affinity for the human MT2 receptor with a Ki value of 1.74 ± 0.26 nM. This resulted in a high MT1 selectivity ratio (MT2/MT1) of 35. [1] In functional assays ([35S]GTPγS binding), S-26131 was found to be inactive as an agonist on both MT1 and MT2 receptors (no dose-response effect observed). [1] S-26131 acted as an antagonist at both MT1 and MT2 receptors. Its antagonist potency, expressed as the equilibrium dissociation constant (Kb), was 5.32 ± 0.95 nM at the MT1 receptor and 143 ± 25 nM at the MT2 receptor. [1] |
| Cell Assay |
Radioligand Binding Assay: The binding affinity of S-26131 for human MT1 and MT2 receptors was determined using cell membranes from human embryonic kidney (HEK 293) cells stably transfected with the respective receptors. The radioligand used was 2-[125I]iodomelatonin. Competition binding experiments were performed with varying concentrations of S-26131. Specific binding was defined using an excess of unlabeled melatonin. The inhibition constant (Ki) was calculated from the concentration causing 50% inhibition of specific radioligand binding (IC50) using the Cheng-Prusoff equation. Concentration-response curves were analyzed by nonlinear regression, and all curves were monophasic with Hill coefficients close to unity. [1]
[35S]GTPγS Binding Functional Assay: The functional activity (agonist or antagonist) of S-26131 was determined using Chinese hamster ovary (CHO) cell lines stably expressing human MT1 or MT2 receptors. For agonist testing, cells were incubated with varying concentrations of the compound, and stimulation of [35S]GTPγS binding was measured. For antagonist testing, cells were pre-incubated with S-26131 before adding a fixed, submaximal concentration of melatonin (30 nM for MT1, 3 nM for MT2). The inhibition of melatonin-stimulated [35S]GTPγS binding was measured, and the antagonist dissociation constant (Kb) was calculated. Agonist efficacy (Emax) was expressed as a percentage of the maximal response induced by 1 μM melatonin. [1] |
| References | |
| Additional Infomation |
We report the first synthesis of an agomelatine (N-[2-(7-methoxynaphthyl-1-yl)ethyl]acetamide) dimer and its binding properties with MT(1) and MT(2) receptors. The dimer consists of two agomelatine units linked by their methoxy substituents via polymethylene side chains, conforming to the “divalent ligand” design concept. Some compounds exhibit MT(1) selective ligand activity. Among them, compound (5) with the highest selectivity exhibits antagonist activity. [1]
S-26131 (compound 5) is an agomelatine dimer derivative designed according to the “divalent ligand” design concept. It consists of two agomelatine units linked by their 7-methoxy substituents via a polymethylene spacer chain containing three methylene units. [1] The main purpose of synthesizing this compound was to obtain a selective MT1 receptor ligand, since there were no selective MT1 agonists or antagonists at that time. [1] Of the series of dimers tested, S-26131 was identified as the compound with the highest MT1 selectivity, with an MT2/MT1 selectivity ratio of 35. The optimal spacer length for MT1 selectivity is three methylene units. [1] This compound functions as an MT1 selective antagonist. Its MT1 selectivity is thought to stem from steric hindrance, where the large substituent (dimer link at position 7) can be accommodated in or near the MT1 receptor binding pocket, but not in the MT2 receptor binding pocket. [1] |
| Molecular Formula |
C31H34N2O4
|
|---|---|
| Molecular Weight |
498.62763
|
| Exact Mass |
498.25
|
| Elemental Analysis |
C, 74.67; H, 6.87; N, 5.62; O, 12.83
|
| CAS # |
296280-56-3
|
| PubChem CID |
9870523
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.168±0.06 g/cm3(Predicted)
|
| Boiling Point |
804.6±65.0 °C(Predicted)
|
| LogP |
5.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
37
|
| Complexity |
657
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCOC3=CC4=C(C=CC=C4CCNC(=O)C)C=C3
|
| InChi Key |
NSXBZYDTTKLTOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H34N2O4/c1-22(34)32-16-14-26-8-3-6-24-10-12-28(20-30(24)26)36-18-5-19-37-29-13-11-25-7-4-9-27(31(25)21-29)15-17-33-23(2)35/h3-4,6-13,20-21H,5,14-19H2,1-2H3,(H,32,34)(H,33,35)
|
| Chemical Name |
N-[2-[7-[3-[8-(2-acetamidoethyl)naphthalen-2-yl]oxypropoxy]naphthalen-1-yl]ethyl]acetamide
|
| Synonyms |
S 26131; 296280-56-3; N-[2-[7-[3-[8-(2-acetamidoethyl)naphthalen-2-yl]oxypropoxy]naphthalen-1-yl]ethyl]acetamide; CHEMBL429392; N,N'-(((Propane-1,3-diylbis(oxy))bis(naphthalene-7,1-diyl))bis(ethane-2,1-diyl))diacetamide; S26131; S-26131
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~31.25 mg/mL (~62.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (2.51 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0055 mL | 10.0275 mL | 20.0550 mL | |
| 5 mM | 0.4011 mL | 2.0055 mL | 4.0110 mL | |
| 10 mM | 0.2005 mL | 1.0027 mL | 2.0055 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA